ChemGenex Of Australia Seeks Funds To Develop First Drug In U.S.
This article was originally published in PharmAsia News
Executive Summary
Australia's ChemGenex Pharmaceuticals is attempting to raise funds to cover the cost of bringing its first drug to market, omacetaxine mepesuccinate for chronic myelogenous leukemia. The drug is intended for patients who no longer respond to drugs geared to treat the leukemia, and made by Novartis and Bristol-Myers Squibb. ChemGenex seeks to raise enough funding to allow it to apply for U.S. approval by mid-year. (Click here for more
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.